Pharming Group reports first quarter 2024 financial results and provides business update $PHAR
Pharming Group reports fourth quarter and full year 2023 financial results
$PHAR
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
$PHAR
7
575
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
$PHAR
Pharming Group reports third quarter 2023 financial results
$PHAR
Forum for Long-term Shareholders in Pharming Group retweeted
Beursblik: Van Lanschot Kempen zet Pharming op de kooplijst deaandeelhouder.nl/nieuws/20…
Pharming Group to participate in September investor conferences
$PHAR
7
520
Pharming Group to convene Extraordinary General Meeting of Shareholders
$PHAR
CEO-Talk: Sijmen de Vries (Pharming) youtu.be/lK0OUHtGgws via @YouTube
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
$PHAR
Pharming Group reports second quarter and first half 2023 financial results
$PHAR
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
$PHAR
8
368
Pharming announces sale of priority review voucher
$PHAR
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders
$PHAR
1
3
554
Pharming Group reports financial results for the first quarter of 2023
$PHAR
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023
$PHAR
5
375
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023
$PHAR
Notice of First Quarter 2023 Results
$PHAR
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
$PHAR
#PharmingGroup $PHAR
Weekoverzicht KW13
Open: 1,374; close: 1,225 (-10,84%)
t.o.v. slot KW12: +23,05%;
High: 1,374; low: 1,109;
Volume: 154.674.800
5
402



























